BACKGROUND: Vgamma9(+)Vdelta2(+) gammadelta T cells (Vdelta 2(+) T cells) are activated by Mycobacterium tuberculosis and secrete interferon (IFN)-gamma. Vdelta 2(+) T cells recognize phosphoantigens, such as bromohydrin pyrophosphate (BrHPP), and link innate and adaptive immunity. METHODS: A whole-blood assay was developed that used IFN-gamma secretion in response to BrHPP as a measurement of Vdelta2(+) T cell function. RESULTS: Peak IFN-gamma levels were detected after stimulating whole blood with BrHPP for 7-9 days. IFN- gamma production in whole blood in response to BrHPP paralleled IFN-gamma production and Vdelta2(+) T cell expansion of peripheral-blood mononuclear cells. The assay was used to evaluate Vdelta2(+) T cell function in subjects in the United States (n = 24) and Uganda (n = 178) who were or were not infected with M. tuberculosis and/or human immunodeficiency virus (HIV) type 1. When 50 micromol/L BrHPP was used, 100% of healthy subjects produced IFN-gamma. The Vdelta2(+) T cell response was independent of the tuberculin skin test response. In Uganda, Vdelta2(+) T cell responses were decreased in patients with tuberculosis (n = 73) compared with responses in household contacts (n = 105). HIV-1-positive household contacts had lower responses than did HIV-1-negative household contacts. HIV-1-positive patients with tuberculosis had the lowest V delta 2(+) T cell responses. CONCLUSIONS: Tuberculosis and HIV-1 infection are associated with decreased Velta2(+) T cell function. Decreased Vdelta2(+) T cell function may contribute to increased risk for tuberculosis in HIV-1-positive patients.
BACKGROUND: Vgamma9(+)Vdelta2(+) gammadelta T cells (Vdelta 2(+) T cells) are activated by Mycobacterium tuberculosis and secrete interferon (IFN)-gamma. Vdelta 2(+) T cells recognize phosphoantigens, such as bromohydrin pyrophosphate (BrHPP), and link innate and adaptive immunity. METHODS: A whole-blood assay was developed that used IFN-gamma secretion in response to BrHPP as a measurement of Vdelta2(+) T cell function. RESULTS: Peak IFN-gamma levels were detected after stimulating whole blood with BrHPP for 7-9 days. IFN- gamma production in whole blood in response to BrHPP paralleled IFN-gamma production and Vdelta2(+) T cell expansion of peripheral-blood mononuclear cells. The assay was used to evaluate Vdelta2(+) T cell function in subjects in the United States (n = 24) and Uganda (n = 178) who were or were not infected with M. tuberculosis and/or human immunodeficiency virus (HIV) type 1. When 50 micromol/L BrHPP was used, 100% of healthy subjects produced IFN-gamma. The Vdelta2(+) T cell response was independent of the tuberculin skin test response. In Uganda, Vdelta2(+) T cell responses were decreased in patients with tuberculosis (n = 73) compared with responses in household contacts (n = 105). HIV-1-positive household contacts had lower responses than did HIV-1-negative household contacts. HIV-1-positivepatients with tuberculosis had the lowest V delta 2(+) T cell responses. CONCLUSIONS:Tuberculosis and HIV-1 infection are associated with decreased Velta2(+) T cell function. Decreased Vdelta2(+) T cell function may contribute to increased risk for tuberculosis in HIV-1-positivepatients.
Authors: F Dieli; M Troye-Blomberg; J Ivanyi; J J Fournié; M Bonneville; M A Peyrat; G Sireci; A Salerno Journal: Eur J Immunol Date: 2000-05 Impact factor: 5.532
Authors: F Martini; R Urso; C Gioia; A De Felici; P Narciso; A Amendola; M G Paglia; V Colizzi; F Poccia Journal: Immunology Date: 2000-08 Impact factor: 7.397
Authors: C Gioia; C Agrati; D Goletti; D Vincenti; S Carrara; M Amicosante; M Casarini; S Giosue; G Puglisi; A Rossi; V Colizzi; L P Pucillo; F Poccia Journal: Int J Immunopathol Pharmacol Date: 2003 Sep-Dec Impact factor: 3.219
Authors: C Bottino; G Tambussi; S Ferrini; E Ciccone; P Varese; M C Mingari; L Moretta; A Moretta Journal: J Exp Med Date: 1988-08-01 Impact factor: 14.307
Authors: C Scott Mahan; Sarah Zalwango; Bonnie A Thiel; LaShaunda L Malone; Keith A Chervenak; Joy Baseke; Dennis Dobbs; Catherine M Stein; Harriet Mayanja; Moses Joloba; Christopher C Whalen; W Henry Boom Journal: Am J Trop Med Hyg Date: 2012-04 Impact factor: 2.345
Authors: Gillian F Black; Bonnie A Thiel; Martin O Ota; Shreemanta K Parida; Richard Adegbola; W Henry Boom; Hazel M Dockrell; Kees L M C Franken; Annemiek H Friggen; Philip C Hill; Michel R Klein; Maeve K Lalor; Harriet Mayanja; Gary Schoolnik; Kim Stanley; Karin Weldingh; Stefan H E Kaufmann; Gerhard Walzl; Tom H M Ottenhoff Journal: Clin Vaccine Immunol Date: 2009-06-24